The FDA did not distort the approval in the orphan drug case, a D.C. court says

By Lauren Berg (October 30, 2024, 11:48 p.m. EDT) — The U.S. Food and Drug Administration did not err when it determined that a competing narcolepsy treatment was not the “same drug” as Jazz's exclusive treatment Pharmaceuticals, a DC Federal judge ruled Wednesday that the FDA's approval of the competing drug did not conflict with the Orphan Drug Act.

Law360 is there, so you are too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments, so you can act quickly and confidently. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features like

• Daily newsletters
• Expert analysis
• Mobile app
• Advanced search
• Information about the judge
• Real-time alerts
• Over 450,000 searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.